New pill aims to boost power of popular weight loss drugs
NCT ID NCT07446998
Summary
This study aims to see if adding a new oral medication called enobosarm to the injectable weight loss drug semaglutide helps people lose more weight than semaglutide alone. It will enroll 200 adults aged 65 and older with obesity. The main goal is to measure total body weight change after about 68 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MOBILITY DISABILITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IMIC Research a Rovia Clinical Research Company
Miami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universal Axon Clinical Research (Rovia - UACR)
Doral, Florida, 33166, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.